Figure 5

Changes in endothelial dysfunction markers: (A) NO pathway intermediates arginine, ADMA and SDMA and (B) methionine cycle intermediates HCy, SAM and SAH in healthy (+/+) and cystic (Cy/+) Han:SPRD rats. Cy/+ rats were additionally treated with 4 mg/kg/day lovastatin for 5 weeks. Significance levels are given for Cy/+ control versus +/+ control and Cy/+ plus lovastatin versus Cy/+ control: *p < 0.05 vs. Cy/+ plus lovastatin, **p < 0.01 vs. Cy/+, ***p < 0.001 vs. Cy/+ plus lovastatin; n = 5-15.